Sinovac Biotech (SVA)

Sinovac’s portfolio addresses a broad range of infectious diseases. Its products and development programmes include vaccines for hepatitis A, hepatitis B, seasonal influenza, pandemic influenza strains such as H5N1 and H1N1, enterovirus 71, pneumococcal disease, polio, varicella, mumps, tetanus, and coronavirus. The company is widely known internationally for CoronaVac, its inactivated COVID-19 vaccine, while its broader business remains centred on routine and outbreak-related immunisation needs.

The company generates most of its revenue in Mainland China, where vaccine demand is shaped by public health programmes, private market vaccination, regulatory standards, and procurement decisions. Its manufacturing base and commercial infrastructure are designed to serve large-scale immunisation markets, where reliability, safety data, production capacity, and compliance with health authority requirements are central to competitiveness.

Sinovac is distinctive because it specialises in human vaccines rather than a broad mix of pharmaceutical products. This gives it concentrated exposure to disease prevention, government vaccination policy, epidemiological trends, and public confidence in vaccine programmes. For investors following the stock, key considerations include product approvals, batch release and manufacturing performance, competitive dynamics among Chinese and global vaccine producers, demand for adult and paediatric immunisation, and the company’s ability to sustain revenue beyond periods of exceptional pandemic-related demand.